Bulls and Bears Place Their Bets On BioCryst (BCRX)
More News related to BCRX
- BioCryst Pharma (BCRX) Priced 5M Common Offering at $9.75/Share
- BioCryst Announces Pricing of Public Offering of Common Stock
- Momentum Mover BioCryst (BCRX) Down On Stock Offering
- BioCryst Pharma (BCRX) Files 5M Common Stock Shelf
- BioCryst Announces Proposed Public Offering of Common Stock
BioCryst Pharmaceuticals (Nasdaq: BCRX), which has been en fuego recently after receiving orders from the U.S. for 10,000 courses of intravenous peramivir for H1N1, could be a battleground stock today.
Today the New York Times reported that late Thursday the government announced orders for intravenous versions of Tamiflu and Relenza, which are much cheaper than BioCryst's peramivir.
The Times suggests BioCryst could give up their gains on the news.
But bulls claim that BioCryst's star is just starting to shine, as swine flu spreads across the country. The beginning of the Times article describes the case of a woman on her death bead from swine flu that recovered after receiving BioCryst's drug. Biotech investors often invest in hope - and the hope for peramivir looks promising.
Either way, up or down today, the BioCryst story it not ending it has just started.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-0.51Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
